A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Nuvisertib (Primary) ; Momelotinib; Ruxolitinib
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology; Tolero Pharmaceuticals
Most Recent Events
- 12 Jun 2025 According to Sumitomo Pharma America media release, the updated preliminary data from this study, presented at the European Hematology Association (EHA) 2025 Congress in Milan, Italy
- 09 Dec 2024 According to Sumitomo Pharma Media Release, data from this trial presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition.
- 09 Dec 2024 Results published in the Sumitomo Pharma Media Release